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Abstract
Glycyrrhizin is known to exert antiviral and anti-inflammatory effects. Here, the effects of an approved parenteral
glycyrrhizin preparation (Stronger Neo-Minophafen C) were investigated on highly pathogenic influenza A H5N1 virus
replication, H5N1-induced apoptosis, and H5N1-induced pro-inflammatory responses in lung epithelial (A549) cells.
Therapeutic glycyrrhizin concentrations substantially inhibited H5N1-induced expression of the pro-inflammatory molecules
CXCL10, interleukin 6, CCL2, and CCL5 (effective glycyrrhizin concentrations 25 to 50 mg/ml) but interfered with H5N1
replication and H5N1-induced apoptosis to a lesser extent (effective glycyrrhizin concentrations 100 mg/ml or higher).
Glycyrrhizin also diminished monocyte migration towards supernatants of H5N1-infected A549 cells. The mechanism by
which glycyrrhizin interferes with H5N1 replication and H5N1-induced pro-inflammatory gene expression includes inhibition
of H5N1-induced formation of reactive oxygen species and (in turn) reduced activation of NFkB, JNK, and p38, redox-
sensitive signalling events known to be relevant for influenza A virus replication. Therefore, glycyrrhizin may complement
the arsenal of potential drugs for the treatment of H5N1 disease.
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Introduction
Highly pathogenic H5N1 influenza A viruses are considered to
be potential influenza pandemic progenitors [1–6]. At least for the
first wave of an H5N1 pandemic, no sufficient amounts of
adequate vaccines will be available [1–4,6–8]. Therefore, antiviral
therapy for influenza A viruses including highly pathogenic H5N1
virus strains remains of great importance for the first line defense
against the virus [1–4,6,9].
The neuraminidase inhibitors oseltamivir and zanamivir as well
as the adamantanes amantadin and rimantadin that interfere with
the influenza M2 protein are licensed for the treament of influenza
[1–4,6]. However, the use of both drug classes is limited by the
emergence of resistant virus strains. In seasonal influenza strains,
the majority of H3N2 viruses and a great proportion of H1N1
viruses in humans are now considered to be amantadine- and
rimantadine-resistant [10–13]. Moreover, a drastic increase in
oseltamivir-resistant H1N1 viruses has been reported during the
2007/2008 influenza season in the northern hemisphere [14–17].
Preliminary data from the United States predict a further rise for
the 2008/2009 season, possibly resulting in more than 90% of the
circulating H1N1 strains to be oseltamivir resistant [14].
H5N1 virus strains appear to be generally less sensitive to
antiviral treatment than seasonal influenza A virus strains and
treatment-resistant H5N1 strains emerge [1–4,6,18–21]. More-
over, parenteral agents for the treatment of seriously ill patients are
missing. Glycyrrhizin, a triterpene saponine, is a constituent of
licorice root. It has been found to interfere with replication and/or
cytopathogenic effect (CPE) induction of many viruses including
respiratory viruses such as respiratory syncytial virus, SARS
coronavirus, HIV, and influenza viruses [22–28]. Moreover, anti-
inflammatory and immunomodulatory properties were attributed
to glycyrrhizin [26]. The severity of human H5N1 disease has
been associated with hypercytokinaemia (‘‘cytokine storm’’)
[29,30]. Delayed antiviral plus immunomodulator treatment
reduced H5N1-induced mortality in mice [31]. Therefore, anti-
inflammatory and immunomodulatory effects exerted by glycyr-
rhizin may be beneficial for treatment of H5N1. Also, glycyrrhizin
is a known antioxidant [26] and antioxidants were already shown
to interfere with influenza A virus replication and virus-induced
pro-inflammatory responses [32–34].
Stronger Neo-Minophagen C (SNMC) is a glycyrrhizin
preparation (available as tablets or parenteral formulation) that
is approved in Japan for the treatment of chronic hepatic diseases
and is marketed in Japan, China, Korea, Taiwan, Indonesia,
India, and Mongolia. Here, we investigated the influence of
SNMC on H5N1 replication, on H5N1-induced cytokine
expression, on H5N1-induced cellular oxidative stress, and on
critical H5N1-induced cellular signalling events in human
pneumocytes (A549 cell line).
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Drugs
Glycyrrhizin (Stronger Neo Minophagen C) was obtained from
Minophagen Pharmaceuticals Co., Ltd. (Tokyo, Japan).
Virus strains
The influenza strain A/Vietnam/1203/04 (H5N1) was received
from the WHO Influenza Centre (National Institute for Medical
Research, London, UK). The H5N1 influenza strain A/Thailand/
1(Kan-1)/04 was obtained from Prof. Pilaipan Puthavathana
(Mahidol University, Bangkok, Thailand).
Virus stocks were prepared by infecting Vero cells (African green
monkey kidney; ATCC, Manassas, VA) and aliquots were stored at
280uC. Virus titres were determined as 50% tissue culture infectious
dose (TCID50/ml) in confluent Vero cells in 96-well microtiter plates.
Cells
A549 cells (human lung carcinoma; ATCC: CCL-185, obtained
from LGC Standards GmbH, Wesel, Germany) were grown at
37uC in minimal essential medium (MEM) supplemented with
10% FBS, 100 IU/ml of penicillin and 100 mg/ml streptomycin.
Human monocytes were isolated from buffy coats of healthy
donors, obtained from Institute of Transfusion Medicine and
Immune Haematology, German Red Cross Blood Donor Center,
Johann Wolfgang Goethe-University, Frankfurt am Main. After
centrifugation on Ficoll (Biocoll)-Hypaque density gradient
(Biochrom AG, Berlin, Germany), mononuclear cells were
collected from the interface and washed with PBS. Then,
monocytes were isolated using magnetically labeled CD14
MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many) following the manufacturer’s instructions. Monocytes were
cultivated in IMDM supplemented with 10% pooled human
serum, 100 IU/ml of penicillin, and 100 mg/ml streptomycin.
Cell viability assay
The cellular viability was assessed on confluent cell layers with
CellTiter-GloH Luminescent Cell Viability Assay (Promega GmbH,
Mannheim, Germany) according to the manufacturers’ protocol.
Cell viability was expressed as percentage of non-treated control.
Detection of influenza A nucleoprotein
To determine intracellular NP localisation, H5N1-infected
A549 were fixed 8 hours p.i. for 15 min with ice-cold acetone/
methanol (40:60, Mallinckrodt Baker B.V., Deventer, The
Netherlands) and stained with a mouse monoclonal antibody
(1 h incubation, 1:1000 in PBS) directed against the influenza A
virus nucleoprotein (NP) (Millipore, Molsheim, France). An Alexa
Fluor 488 goat anti-mouse IgG (H&L) (Invitrogen, Eugene,
Oregon, USA) was used (1 h incubation, 1:1000 in PBS) as
secondary antibody. Nuclei were stained using 49,6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich Chemie GmbH, Munich,
Germany). Fluorescence was visualised using Olympus IX 1
fluorescence microscope (Olympus, Planegg, Germany).
For flow cytometric analysis, the same antibodies were used.
Cytopathogenic effect (CPE) reduction assay
The cytopathogenic effect (CPE) reduction assay was performed
as described before [34]. Confluent A549 cell monolayers grown in
96-wellmicrotitreplateswereinfectedwithinfluenzaA strainsatthe
indicated multiplicities of infection (MOIs). After a one hour
adsorption period, cells were washed to remove non-detached virus.
The virus-induced CPE was recorded at 24 h post infection (p.i.).
Unless otherwise stated, A549 cells were continuously treated with
glycyrrhizin starting with a 1 h pre-incubation period. For time-of-
addition experiments, glycyrrhizin was added exclusively during the
1 h pre-incubation period, exclusively during the 1 h adsorption
period, or after exclusively after the wash-out of input virus.
Real-time PCR
Total RNA was isolated from cell cultures using TRI reagent
(Sigma-Aldrich, Munich, Germany). Real time PCR for H5 was
performed using described methods [35]. The following primers
were used: sense 59 acg tat gac tac ccg cag tat tca g 39; antisense 59
aga cca gcy acc atg att gc 39; probe 6-FAM-tca aca gtg gcg agt tcc
cta gca-TAMRA.
Sub-G1 cells
The fraction of cells with fractional DNA content (‘‘sub-G1’’ cell
subpopulation) indicates cytotoxicity. Sub-G1 cells are considered
to be dead (usually apoptotic) cells. Cells were fixed with 70%
ethanol for two hours at 220uC. The cellular DNA was stained
using propidium iodide (20 mg/ml) and analysed by flow
cytometry (FacsCalibur, BD Biosciences, Heidelberg, Germany).
Caspase activation
Caspase activation was measured using the Caspase-Glo 8, 9, or
3/7 Assays (Promega, Mannheim, Germany) following the
manufacturer’s instructions.
Cytokine/Chemokine secretion
Cell culture supernatants were collected and frozen at 280uC.
Cytokines/chemokines were quantified by specific ELISA Duo
Sets (R&D Systems GmbH, Wiesbaden, Germany) following the
manufacturer’s instructions.
Nuclear factor kB (NFkB) activity
NFkB activity was investigated in H5N1 (MOI 0.01)-infected cells
by quantification of the NFkB subunits Rel A (p65) and NFkB1 (p50)
from nuclear extracts using the TransAM
TM transcription factor
DNA-binding ELISAs (Active Motif, Rixensart, Belgium). Nuclear
extract were prepared using the Nuclear Extract Kit (Active Motif,
Carlsbad, CA, USA) following the manufacturer’s instruction.
Migration assay
Cell culture supernatants were investigated for chemotactic
activity by measurement of the activity to induce monocyte
migration through membrane inserts in 24-well plates (pore size
8 mm; BD Biosciences, Heidelberg, Germany). Monocytes (1610
6
in 100 ml of IMDM with 10% pooled human serum) were added
into the cell culture inserts (upper chamber) and cell culture
supernatants (300 ml), were added to the lower chamber of the
well. After a 48 h incubation period, cells were fixed with 4%
paraformaldehyde and permeabilised with PBS containing 0.3%
Tritron X-100. Then, nuclei were stained with 49,6-diamidino-2-
phenylindole (DAPI). The upper side of the membrane was wiped
with a wet swab to remove the cells, while the lower side of the
membrane was rinsed with PBS. The number of cells at the lower
side of each membrane was quantified by counting of cells from
three randomly chosen sections (3.7 mm
2) using an Olympus IX 1
fluorescence microscope (Olympus, Planegg, Germany).
Western blot
Cells were lysed in Triton X-sample buffer and separated by SDS-
PAGE. Nuclear extract were prepared using the Nuclear Extract Kit
(Active Motif, Carlsbad, CA, USA) following the manufacturer’s
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actin (Sigma-Aldrich Chemie GmbH, Munich, Germany), JNK,
phosphorylated JNK, p38, or phosphorylated p38, (all purchased
from New England Biolabs GmbH, Frankfurt am Main, Germany)
and were visualised by enhanced chemiluminescence using a
commercially available kit (Amersham, Freiburg, Germany).
Determination of cellular oxidative stress
Reactive oxygen species (ROS) were detected using the Image-
iT LIVE Green Reactive Oxygen Species Kit (Molecular Probes,
distributed by Invitrogen, Karlsruhe, Germany).
Statistical analysis
Twogroupswerecomparedbyt-test.Moregroupswerecompared
by ANOVA with subsequent Student-Newman-Keuls test.
Results
Influence of glycyrrhizin on replication of H5N1 virus in
A549 cells
The A549 cell line, derived from a human pulmonary adenocar-
cinoma, is an established model for type II pneumocytes [36], and
commonly used for the investigation of the effect of influenza viruses
on this cell type [see e.g. 6,37,38]. If not otherwise stated, glycyrrhizin
was continuously present in cell culture media starting with a 1 h pre-
infection period. Glycyrrhizin 200 mg/ml (the maximum tested
concentration) did not affect A549 cell viability (data not shown) but
clearly decreased CPE formation in A549 cells infected with the
H5N1 influenza strain A/Thailand/1(Kan-1)/04 at MOIs of 0.01,
0.1 or 1 (Figure 1A). Similar results were obtained in A549 cells
infected with strain A/Vietnam/1203/04 (H5N1) (Suppl. Figure1A).
Staining of A549 cells for influenza A nucleoprotein 24 h after
infection with strain H5N1 A/Thailand/1(Kan-1)/04 indicated that
glycyrrhizin 200 mg/ml significantly reduces the number of influenza
A nucleoprotein positive cells (Figure 1B).
To examine the influence of glycyrrhizin on virus progeny,
A549 cells were infected with the H5N1 influenza strain A/
Thailand/1(Kan-1)/04 at MOI 0.01 or MOI 1 and infectious
virus titres were determined 24 h post infection (Figure 1C). While
glycyrrhizin in concentrations up to 50 mg/ml did not affect H5N1
replication, moderate effects were exerted by glycyrrhizin 100 mg/
ml and more pronounced effects by glycyrrhizin 200 mg/ml (MOI
0.01: 13-fold reduction, MOI 1: 10-fold reduction). Next,
influence of glycyrrhizin on H5N1 replication was confirmed by
the detection of viral (H5) RNA using quantitative PCR. Only
glycyrrhizin concentrations $100 mg/ml significantly reduced
Figure 1. Influence of glycyrrhizin on H5N1 replication in A549 cells. A) Representative pictures of non-infected A549 cells (Mock) and
cytopathogenic effect formation in A549 cells infected with H5N1 A/Thailand/1(Kan-1)/04 at different multiplicities of infection (MOI) without or with
glycyrrhizin (200 mg/ml) treatment for 24 h. B) Influence of glycyrrhizin 200 mg/ml on the number of H5N1 A/Thailand/1(Kan-1)/04-infected A549 cells
determined by flow cytometric analysis of nucleoprotein-positive cells 24 h post infection. C) Influence of different glycyrrhizin concentrationso n
viral titres determined in A549 cells infected with H5N1 A/Thailand/1(Kan-1)/04 (MOI 0.01 or MOI 1) 24 h post infection. D). Influence of different
glycyrrhizin administration schedules on H5N1 A/Thailand/1(Kan-1)/04 (MOI 0.01) viral titres determined in A549 cells 24 h post infection. Cells were
treated without glycyrrhizin (non-treated), with glycyrrhizin 200 mg/ml continuously starting with a 1 h pre-incubation period (continuous treatment),
with glycyrrhizin 200 mg/ml solely for a 1 h pre-incubation period (pre-treatment), with glycyrrhizin 200 mg/ml solely during the 1 h adsorption
period, or with glycyrrhizin 200 mg/ml added after virus adsorption. Pro-longed pre-treatment periods did not result in increased virus inhibitory
effects of the continuous treatment regimen (not shown). * P,0.05 relative to non-treated virus control, # P,0.05.
doi:10.1371/journal.pone.0019705.g001
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(Suppl. Figure 1B) or H5N1 A/Vietnam/1203/04-infected (Suppl.
Figure 1C) A549 cells (MOI 0.01) 24 h post infection.
Time-of-addition experiments revealed that maximal effects
were achieved when glycyrrhizin was continuously present starting
with a 1 h pre-incubation period (Figure 1D). Addition of
glycyrrhizin post infection showed reduced antiviral effects while
pre-incubation alone or glycyrrhizin addition during the adsorp-
tion period did not significantly affect H5N1 replication.
Influence of glycyrrhizin on cytokine production in A549
cells
For investigation of H5N1-induced cytokine expression, five
pro-inflammatory genes were chosen that had been correlated to
severity of influenza disease: CXCL10 (also known as interferon-c-
inducible protein 10, IP-10), interleukin 6 (IL6), interleukin 8,
(IL8; also known as CXCL8), CCL2 (also known as monocyte
chemoattractant protein 1, MCP-1), and CCL5 (also known as
RANTES). A549 cells were infected with H5N1 A/Thailand/
1(Kan-1)/04 or H5N1 A/Vietnam/1203/04 at MOI 0.01, 0.1, or
1. Glycyrrhizin treatment was performed with 25, 50, 100, or
200 mg/ml. Cytokine expression was detected 24 h post infection
by ELISA. Glycyrrhizin did not affect cytokine expression of non-
infected cells (data not shown) but inhibited expression of all
cytokines investigated in H5N1-infected cells in a dose-dependent
manner (Figure 2, Figure 3A). Effects were more pronounced at
lower MOIs. Notably, expression of all cytokines except IL8 was
significantly inhibited after treatment with glycyrrhizin 50 mg/ml
Figure 2. Influence of glycyrrhizin on H5N1-induced expression of CXCL10, IL6, and IL8 in A549 cells. Excretion of cytokines by non-
infected (Mock) A549 cells or A549 cells infected with different H5N1 strains at different MOIs 24 h post infection determined by ELISA. For each MOI
five bars are presented. From the left to the right these bars represent: untreated virus control, glycyrrhizin 25 mg/ml, glycyrrhizin 50 mg/ml,
glycyrrhizin 100 mg/ml, glycyrrhizin 200 mg/ml. * P,0.05 relative to non-treated virus control.
doi:10.1371/journal.pone.0019705.g002
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these glycyrrhizin concentrations had no effect on H5N1
replication in A549 cells (Figure 1, Figure S1).
Influence of glycyrrhizin on monocyte recruitment of
H5N1-infected A549 cells
Cytokine expression by influenza A virus-infected respiratory
cells causes recruitment of peripheral blood monocytes into the
lungs of patients where they differentiate to macrophages which
are thought to contribute to influenza A virus pathogenicity [5,39].
In a chemotaxis assay, the influence of glycyrrhizin was
investigated on migration of monocytes towards supernatants of
H5N1 A/Thailand/1(Kan-1)/04 (MOI 0.1)-infected A549 cells
through 8 mm filters. Monocyte migration towards supernatants of
H5N1-infected cells was strongly increased relative to migration
towards supernatants of non-infected cells. Treatment of H5N1-
Figure 3. Influence of glycyrrhizin on H5N1-induced expression of CCL2 and CCL5 in A549 cells and on monocyte migration
towards supernatants of H5N1-infected A549 cells. A) Excretion of cytokines by non-infected (Mock) A549 cells or A549 cells infected with
different H5N1 strains at different MOIs 24 h post infection determined by ELISA. For each MOI five bars are presented. From the left to the right
these bars represent: untreated virus control, glycyrrhizin 25 mg/ml, glycyrrhizin 50 mg/ml, glycyrrhizin 100 mg/ml, glycyrrhizin 200 mg/ml. * P,0.05
relative to non-treated virus control. B) Representative pictures of monocytes migrated towards supernatants of H5N1-infected A549 cells and
quantification of migrated monocytes towards supernatants of H5N1-infected A549 cells relative to supernatants of non-treated Mock cells. Primary
human monocytes (10
6 cells) were seeded on 8 mm filters. The filters were placed into wells containing supernatants of non-infected (Mock) or H5N1
A/Thailand/1(Kan-1)/04 (MOI 0.1)-infected glycyrrhizin (100 mg/ml)-treated or non-treated A549 cells. After 24 h, the migrated monocytes were
quantified after fixation and DAPI staining of the cells attached to the lower surface of the membranes. Five random fields (each 0.25 mm
2) were
counted at 2006magnification. * P,0.05 relative to supernatants of non-treated Mock cells.
doi:10.1371/journal.pone.0019705.g003
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chemoattraction activity of supernatants (Figure 3B).
Influence of glycyrrhizin on H5N1-induced caspase
activation and nuclear export of ribonucleoprotein (RNP)
complexes
Influenza viruses including H5N1 have been shown to induce
caspase-dependent apoptosis in airway cells and this apoptosis has
been correlated to the virus pathogenicity [40,41]. Glycyrrhizin
concentrations up to 200 mg/ml did not affect caspase activation
in non-infected cells (Figure 4A–C). Glycyrrhizin concentrations
$100 mg/ml inhibited H5N1 A/Thailand/1(Kan-1)/04 (MOI
0.01)-induced activation of the initiator caspases 8 and 9 as well as
of the effector caspases 3/7 in A549 cells as determined 24 h post
infection (Figure 4A–C). Lower glycyrrhizin concentrations did
not affect H5N1-induced apoptosis. The detection of cells in sub-
G1 phase resulted in similar findings (Figure 4D).
Substances that inhibit H5N1-induced caspase 3 activation
including caspase 3 inhibitors cause nuclear retention of RNP
complexes [34,42]. In accordance, glycyrrhizin also interfered
with nuclear export RNP at MOI 1 (Figure S2). Similar results
were obtained in MOI 0.01 H5N1 A/Thailand/1(Kan-1)/04-
infected cells (Figure S3).
Influence of glycyrrhizin on H5N1-induced activation of
nuclear factor kB (NFkB), p38, and on H5N1-induced
cellular reactive oxygen species (ROS) formation
Activation of NFkB, p38, and JNK have been associated with
influenza A virus replication and virus-induced pro-inflammatory
gene expression [34,43–47]. While glycyrrhizin did not influence
NFkB activity in non-infected A549 cells in the tested concentra-
tions (data not shown), glycyrrhizin inhibited NFkB activation in
H5N1-infected cells (Figure 5A). Moreover, glycyrrhizin inhibited
H5N1-induced phosphorylation of the MAPKs p38 and JNK
(Figure 5B).
In addition to their roles during influenza A virus replication
and virus-induced cytokine/chemokine expression, NFkB, p38,
and JNK are constituents of redox-sensitive signalling pathways
[48–51]. Antioxidants had been already found to interfere with
influenza A virus-induced signalling through NFkB, p38, and
JNK, with influenza A virus replication, and with influenza A
virus-induced pro-inflammatory gene expression [32–34]. Since
glycyrrhizin is known to exert antioxidative effects [26] we
speculated that glycyrrhizin may interfere with H5N1-induced
ROS formation. Indeed glycyrrhizin exerted clear antioxidative
effects in H5N1 (MOI 0.01)-infected cells (Figure 5C) causing
significant reduction of ROS formation already at a concentration
of 25 mg/ml (Figure 5D).
Discussion
Here, we show that glycyrrhizin inhibits the replication of highly
pathogenic H5N1 influenza A virus, H5N1-induced apoptosis,
and H5N1-induced expression of pro-inflammatory cytokines in
lung-derived A549 cells. After intravenous administration, achiev-
able plasma concentrations of glycyrrhizin have been described to
be about 100 mg/ml [52]. Therefore, the glycyrrhizin concentra-
tions found to interfere with H5N1 replication and H5N1-induced
pro-inflammatory gene expression in the present report are in the
range of therapeutic plasma levels. Notably, although higher
glycyrrhizin concentrations were needed to interfere with SARS
coronavirus replication [22] than with H5N1 replication,
beneficial results were reported in glycyrrhizin (SNMC)-treated
Figure 4. Influence of glycyrrhizin on H5N1-induced caspase activation and cells in sub-G1 phase. Caspase activation (A–C) or fraction of
cells in sub-G1 phase (D) were measured in non-infected (Mock) or H5N1 A/Thailand/1(Kan-1)/04 (MOI 0.01)-infected glycyrrhizin-treated or non-
treated A549 cells 24 h post infection.
doi:10.1371/journal.pone.0019705.g004
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receive glycyrrhizin [23]. Notably, investigation of different
glycyrrhizin derivatives against SARS coronavirus led to the
identification of compounds with enhanced antiviral activity [53].
Therefore, glycyrrhizin might also serve as lead structure for the
development of novel anti-influenza drugs.
Experimental results suggested that glycyrrhizin might be able
to affect seasonal influenza A virus disease by antiviral and
immunomodulatory effects [26,27]. Mice were prevented from
lethal H2N2 infection by glycyrrhizin although no influence on
virus replication was detected. The mechanism was suggested to
be induction of interferon-c in T-cells by glycyrrhizin [54].
Moreover, glycyrrhizin was shown to influence seasonal influenza
A virus replication through interaction with the cell membrane
[25,28]. However, these effects were observed only in concentra-
tions $200 mg/ml when glycyrrhizin was added during the virus
adsorption period. Since glycyrrhizin addition during the adsorp-
tion period did not influence H5N1 replication in our experiments
it appears not likely that membrane effects contribute to anti-
H5N1 effects detected here in lower concentrations.
Our results rather suggest that glycyrrhizin interferes with
H5N1-induced oxidative stress. Influenza A virus (including
H5N1) infection induces ROS formation. Antioxidants were
found to inhibit influenza A virus replication and influenza A
virus-induced pro-inflammatory gene expression [32–34] and
glycyrrhizin is known to exert antioxidative effects [26]. Here,
glycyrrhizin interfered with H5N1-induced activation of NFkB,
p38, and JNK representing redox-sensitive signalling events [48–
51] involved in influenza A virus replication and influenza A virus-
induced cellular cytokine/chemokine production [34,43–46,55].
Glycyrrhizin 50 mg/ml significantly reduced H5N1-induced
activation of NFkB. In addition, glycyrrhizin concentrations as
low as 25 mg/ml effectively interfered with H5N1-induced ROS
formation and with phosphorylation of the redox-sensitive
MAPKs p38 and JNK. In our model, activation of p38 appears
to be critical for H5N1-associated redox signalling since p38
Figure 5. Influence of glycyrrhizin on activation of NFkB, p38, and on H5N1-induced formation of reactive oxygen species (ROS). A)
NFkB activity examined by determination of the activities of the NFkB subunits p65 (black bars) and p50 (grey bars) in non-infected (MOCK) or H5N1
A/Thailand/1(Kan-1)/04 (MOI 0.01)-infected glycyrrhizin-treated or non-treated A549 cells 24 h post infection. * P,0.05 relative to non-treated virus
control. B) Western blots showing levels of p38, phosphorylated p38 (pp38), JNK, phosphorylated JNK (pJNK), or b-actin (loading control) in non-
infected or H5N1 A/Thailand/1(Kan-1)/04 (MOI 0.01)-infected glycyrrhizin-treated or non-treated A549 cells 1 h post infection. C) Representative
pictures showing H5N1 A/Thailand/1(Kan-1)/04 (MOI 0.01)-induced ROS formation in the presence or absence of glycyrrhizine 100 mg/ml (gly) 24h
post infection in A549 cells. ROS are indicated in green. Nuclei are DAPI-stained (blue). D) Quantification of ROS-positive cells with or without
glycyrrhizin treatment. * P,0.05 relative to non-treated virus control.
doi:10.1371/journal.pone.0019705.g005
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antioxidant N-acetyl-cysteine (NAC) [34]. Interestingly and in
contrast to glycyrrhizin, NAC failed to inhibit H5N1 replication or
H5N1-induced cytokine/chemokine expression in therapeutically
relevant concentrations.
Glycyrrhizin diminished H5N1-induced cellular cytokine/
chemokine production in concentrations (#50 mg/ml) that did
not interfere with H5N1 replication although redox-sensitive
signalling pathways have been described to be involved in both
processes. Therefore, H5N1-induced proinflammatory gene
expression appears to be more sensitive to inhibition of ROS
formation than H5N1 replication. Indeed, influenza viruses had
been shown to induce cellular pathways through replication-
dependent and –independent events [56]. In a previous report, we
could show that similar glycyrrhizin concentrations like those
investigated here interfered with H5N1-induced pro-inflammatory
gene expression but not with H5N1 replication in human
monocyte-derived macrophages [57]. In addition, other immuno-
modulatory treatment regimens that did not influence H5N1
replication reduced mortality in H5N1-infected mice [31,58].
Therefore, glycyrrhizin represents a potential additional treatment
option that interfers with both H5N1 replication and H5N1-
induced expression of pro-inflammatory cytokines in lung cells.
Interference with immune responses may also result in the loss
of control of virus replication by cytotoxic immune cells including
natural killer cells and cytotoxic CD8
+ T-lymphocytes. Global
immunosuppressants like corticosteroids failed to protect from
lethal influenza virus infection [59]. Moreover, antiviral drugs may
interfere with cytotoxic cells that control virus replication as
demonstrated for ribavirin that was shown to hamper NK cell
cytolytic activity [60]. In this context, glycyrrhizin had already
been shown not to affect natural killer cell activity in the
concentrations used here [57].
In conclusion, we show in this report that therapeutic
concentrations of glycyrrhizin (used as clinically approved
parenteral preparation SNMC) interfere with highly pathogenic
H5N1 influenza A virus replication and H5N1-induced pro-
inflammatory gene expression at least in part through interference
with H5N1-induced ROS formation and in turn reduced
activation of p38, JNK, and NFkB in lung cells. Since we used
the clinical formulation SNMC effects of other ingredients like
glycin or cystein cannot be excluded. Vaccines and antiviral agents
will fail to meet global needs at least at the beginning of a severe
influenza A virus pandemic [61]. Anti-inflammatory and immu-
nomodulatory agents are considered to be important candidates as
constituents of anti-influenza treatment strategies that may save
lives in an influenza pandemic situation [61]. Therefore,
glycyrrhizin may complement the arsenal of potential drugs for
the treatment of H5N1-caused disease.
Supporting Information
Figure S1 Influence of glycyrrhizin on H5N1 replication
inA549cells.A)Representativepicturesofnon-infectedA549 cells
(Mock) and cytopathogenic effect formation in A549 cells infected
with H5N1 strain A/Vietnam/1203/04 at different multiplicities of
infection (MOI) without or with glycyrrhizin (200 mg/ml) treatment
for 24 h. B) and C) Effect of different glycyrrhizin concentrations on
expression of influenza RNA detected byquantitative PCR inH5N1
A/Thailand/1(Kan-1)/04-infected (B) or A/Vietnam/1203/04-
infected (C) A549 cells (MOI 0.01) 24 h post infection. * P,0.05
relative to non-treated control.
(PDF)
Figure S2 Influence of glycyrrhizin on nuclear export of
influenza A virus ribonucleoprotein (RNP) complexes.
Influence of glycyrrhizine (Gly) on nuclear export of viral NP
indicating RNP complexes in H5N1 A/Thailand/1(Kan-1)/04
(MOI 1)-infected A549 cells 8 h p.i. RNP localisation (green) was
visualised by fluorescence microscopy using an antibody directed
against influenza A NP. Nuclei are stained by DAPI (shown in
blue).
(PDF)
Figure S3 Influence of glycyrrhizin on nuclear export of
influenza A virus ribonucleoprotein (RNP) complexes.
Influence of glycyrrhizine (Gly) on nuclear export of viral NP
indicating RNP complexes in H5N1 A/Thailand/1(Kan-1)/04
(MOI 0.01)-infected A549 cells 8 h p.i. RNP localisation (green)
was visualised by fluorescence microscopy using an antibody
directed against influenza A NP. Nuclei are stained by DAPI
(shown in blue).
(PDF)
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